Lovehaaning7181

should still be offered, based on participant preference. Customising e-consenting platforms may improve accessibility for individuals with specific needs, and increase engagement with study information. Research teams must offer prospective participants opportunities to discuss study information in real-time.

E-consent may facilitate remotely-conducted research by offering a feasible and robust alternative to face-to-face consenting approaches, however paper-based options should still be offered, based on participant preference. Customising e-consenting platforms may improve accessibility for individuals with specific needs, and increase engagement with study information. Research teams must offer prospective participants opportunities to discuss study information in real-time.

Social media have emerged as a platform for experience and knowledge sharing in the medical community. The online medical community is garnering increasing research attention; however, there is a lack of understanding of what factors influence the helpfulness and engagement of experience sharing in the community.

Clinical documents manifest physicians' experience and knowledge. This study fills the knowledge gap by investigating what elements of clinical documents contribute to the helpfulness of sharing clinical documents online and what influence member engagement. Clinical documents follow certain architecture to specify their structure and semantics for exchange (e.g., HL7 C-CDA). selleck products Accordingly, the structural elements of clinical documents may influence document helpfulness for the online community. Member engagement is one of the indicators of community success. We collected 6514 clinical documents from a real-world online medical community, and normalized them with the structural elements of HL7 C-CDe quality of medical decisions.

The findings provide guide on how to improve the effectiveness of sharing clinical experience online. The new and in-depth insights may contribute to the success of online medical communities and the quality of medical decisions.

Hospital admission is a frequent occurrence among patients with cancer, and a significant proportion of patients admitted to medical units have cancer. Their hospital stay has features that may be different compared with patients without cancer. We performed a retrospective analysis of the characteristics of patients with cancer admitted for medical conditions.

We studied the administrative data of patients with solid cancer admitted to the medical department of a large referral hospital over a 12-month period and compared them with those of patients without cancer.

Seven thousand eight hundred two consecutive admissions were analysed, of which 1099 (14.1%) had a principal or associated diagnosis of cancer. Admissions were distributed across 12 units, with 44% concentrated in the medical oncology unit and 56% in other units. Patients with cancer were more frequently men and were younger than patients without cancer. Admission less frequently involved the emergency department (ED), while discharge was mo competencies.

Baseline tumour burden is a prognostic factor for patients with melanoma and non-small-cell lung cancer treated with immunotherapy. However, no data are available on its role in other solid tumours, nor for treatment with next-generation immunoncology agents (NGIOs).

We reviewed data of patients with any solid tumour consecutively treated at our institution from August 2014 to March 2019, who received ≥1 dose of immune checkpoint inhibitorand/or NGIO within phase 1 trials. Baseline tumour burden was calculated as ∑i Response Evaluation Criteria in Solid Tumours 1.1 baseline target lesions (baseline tumour size[BTS]) or as sum of all measurable baseline lesions (total tumour burden [TTB]); the impact of both parameters on treatment outcomes was investigated.

One hundred fifty patients were included in the analysis. Median BTS and TTB were 79mm and 212mm, respectively. Objective response rate was found significantly associated with BTS (p<0.001) and TTB quartiles (p=0.006), with response rates progressively increasing with decreasing tumour burden quartiles. Both progression-free survival (PFS) (p=0.001) and overall survival (OS) (p<0.001) were significantly associated with BTS quartiles, with 26% of the patients progression-free and 56% alive at 12 months in the lower BTS quartile, compared with 3% and 24%, respectively, in the upper quartile. TTB was also significantly associated with OS (P=0.01) and borderline-significant for PFS (p=0.07). Multivariate analysis confirmed that baseline burden, also considered as continuous variable, is independently associated with PFS and OS, when assessed with BTS (p=0.001 and p<0.001) and TTB (p=0.007 and p<0.001).

Lower baseline tumour burden is associated with better outcomes in patients with cancer treated with novel immunotherapies.

Lower baseline tumour burden is associated with better outcomes in patients with cancer treated with novel immunotherapies.

Oligometastatic disease (OMD) identifies tumours with limited metastatic spread. OMD definition is not univocal and no data from clinical trials are available about the prognostic effect of OMD in metastatic colorectal cancer (mCRC), the impact of locoregional treatments (LRTs) and the effect of chemotherapy intensification in these patients. The role of tumour burden (TB) in driving therapeutic choices is also debated.

We performed a pooled analysis of phase III TRIBE and TRIBE2 studies comparing FOLFOXIRI/bevacizumab (bev) to doublets (FOLFOX or FOLFIRI)/bev. Patients were grouped in OMD versus non-OMD based on the European Society for Medical Oncology definition. Among patients with OMD, those with OMD/low TB were compared with all the others.

Of 1187 patients enrolled, 1096 were classified as OMD (N=312 [28%]) or non-OMD (N=784 [72%]). Among patients with OMD, 126 (40%) were OMD/low TB. OMD was associated with longer progression-free survival (14.0 versus 10.1 months; p<0.01) and overall survival (38.2 versus 22.0 months; p<0.01). These results were confirmed in multivariable models. The benefit provided by FOLFOXIRI/bev compared with doublets/bev did not differ in accordance with OMD and TB (p for interaction >0.05). Patients with OMD underwent LRTs more frequently (p<0.01) and those with OMD/low TB had higher chance to undergo LRTs after the first progression (p<0.01).

OMD is a positive prognostic factor in mCRC. The benefit from the upfront treatment intensification is independent of the metastatic spread extent and TB. LRTs should be highly considered in these patients, mainly during the first-line therapy but also at later stages of treatment history in selected cases.

OMD is a positive prognostic factor in mCRC. The benefit from the upfront treatment intensification is independent of the metastatic spread extent and TB. LRTs should be highly considered in these patients, mainly during the first-line therapy but also at later stages of treatment history in selected cases.